down arrow

Supernus Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8684591089
USD
45.10
0.98 (2.22%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Harmony Biosciences Holdings, Inc.
IDEAYA Biosciences, Inc.
Vericel Corp.
PTC Therapeutics, Inc.
Xenon Pharmaceuticals, Inc.
Ultragenyx Pharmaceutical, Inc.
Crinetics Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.
Biohaven Ltd.
Neumora Therapeutics, Inc.
Why is Supernus Pharmaceuticals, Inc. ?
1
With a fall in Operating Profit of -16.25%, the company declared Very Negative results in Jun 25
  • PRE-TAX PROFIT(Q) At USD 15.67 MM has Fallen at -32.05%
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 27.65%, its profits have risen by 1413.7% ; the PEG ratio of the company is 0
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Supernus Pharmaceuticals, Inc. for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Supernus Pharmaceuticals, Inc.
21.79%
2.00
38.02%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
9.41%
EBIT Growth (5y)
-16.01%
EBIT to Interest (avg)
19.82
Debt to EBITDA (avg)
0.16
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.63
Tax Ratio
32.55%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
10.50%
ROE (avg)
7.61%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
29
Industry P/E
Price to Book Value
1.80
EV to EBIT
18.64
EV to EBITDA
9.02
EV to Capital Employed
2.44
EV to Sales
2.09
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
13.09%
ROE (Latest)
6.24%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 187.07 MM

DEBT-EQUITY RATIO (HY)

Lowest at -46.13 %

RAW MATERIAL COST(Y)

Fallen by 0.14% (YoY

CASH AND EQV(HY)

Highest at USD 986.19 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 2.8 times

-2What is not working for the Company
PRE-TAX PROFIT(Q)

At USD 15.67 MM has Fallen at -32.05%

Here's what is working for Supernus Pharmaceuticals, Inc.
Operating Cash Flow
Highest at USD 187.07 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debt-Equity Ratio
Lowest at -46.13 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Cash and Eqv
Highest at USD 986.19 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio
Highest at 2.8 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by 0.14% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at USD 21.32 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Supernus Pharmaceuticals, Inc.
Pre-Tax Profit
At USD 15.67 MM has Fallen at -32.05%
over average net sales of the previous four periods of USD 23.06 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Non Operating Income
Highest at USD 0.27 MM
in the last five periods
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating income

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."